JPS6367859B2 - - Google Patents
Info
- Publication number
- JPS6367859B2 JPS6367859B2 JP8734181A JP8734181A JPS6367859B2 JP S6367859 B2 JPS6367859 B2 JP S6367859B2 JP 8734181 A JP8734181 A JP 8734181A JP 8734181 A JP8734181 A JP 8734181A JP S6367859 B2 JPS6367859 B2 JP S6367859B2
- Authority
- JP
- Japan
- Prior art keywords
- groups
- group
- phosphite
- phenyl group
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 39
- 238000009534 blood test Methods 0.000 claims description 35
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 150000008301 phosphite esters Chemical class 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 claims description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 4
- XESZUVZBAMCAEJ-UHFFFAOYSA-N 4-tert-butylcatechol Chemical group CC(C)(C)C1=CC=C(O)C(O)=C1 XESZUVZBAMCAEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000005487 catechin Nutrition 0.000 claims description 4
- 229950001002 cianidanol Drugs 0.000 claims description 4
- BJEMXPVDXFSROA-UHFFFAOYSA-N 3-butylbenzene-1,2-diol Chemical group CCCCC1=CC=CC(O)=C1O BJEMXPVDXFSROA-UHFFFAOYSA-N 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 description 29
- -1 polyethylene Polymers 0.000 description 22
- 230000023555 blood coagulation Effects 0.000 description 20
- 230000001737 promoting effect Effects 0.000 description 12
- 238000000926 separation method Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000012778 molding material Substances 0.000 description 8
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- WRSPWQHUHVRNFV-UHFFFAOYSA-N tris[3,5-di(nonyl)phenyl] phosphite Chemical compound CCCCCCCCCC1=CC(CCCCCCCCC)=CC(OP(OC=2C=C(CCCCCCCCC)C=C(CCCCCCCCC)C=2)OC=2C=C(CCCCCCCCC)C=C(CCCCCCCCC)C=2)=C1 WRSPWQHUHVRNFV-UHFFFAOYSA-N 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920003048 styrene butadiene rubber Polymers 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 229940019700 blood coagulation factors Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- PYFRLDVYGBCYLI-UHFFFAOYSA-N decyl dihydrogen phosphite Chemical compound CCCCCCCCCCOP(O)O PYFRLDVYGBCYLI-UHFFFAOYSA-N 0.000 description 3
- GLOQRSIADGSLRX-UHFFFAOYSA-N decyl diphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OCCCCCCCCCC)OC1=CC=CC=C1 GLOQRSIADGSLRX-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- WGKLOLBTFWFKOD-UHFFFAOYSA-N tris(2-nonylphenyl) phosphite Chemical compound CCCCCCCCCC1=CC=CC=C1OP(OC=1C(=CC=CC=1)CCCCCCCCC)OC1=CC=CC=C1CCCCCCCCC WGKLOLBTFWFKOD-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 239000003822 epoxy resin Substances 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000025 natural resin Substances 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- MQXNNWDXHFBFEB-UHFFFAOYSA-N 2,2-bis(2-hydroxyphenyl)propane Chemical compound C=1C=CC=C(O)C=1C(C)(C)C1=CC=CC=C1O MQXNNWDXHFBFEB-UHFFFAOYSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- JIGUICYYOYEXFS-UHFFFAOYSA-N 3-tert-butylbenzene-1,2-diol Chemical compound CC(C)(C)C1=CC=CC(O)=C1O JIGUICYYOYEXFS-UHFFFAOYSA-N 0.000 description 1
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229920007962 Styrene Methyl Methacrylate Polymers 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- ZOQOJLXIMYWJPF-UHFFFAOYSA-N didecyl (2-nonylphenyl) phosphite Chemical compound CCCCCCCCCCOP(OCCCCCCCCCC)OC1=CC=CC=C1CCCCCCCCC ZOQOJLXIMYWJPF-UHFFFAOYSA-N 0.000 description 1
- NMAKPIATXQEXBT-UHFFFAOYSA-N didecyl phenyl phosphite Chemical compound CCCCCCCCCCOP(OCCCCCCCCCC)OC1=CC=CC=C1 NMAKPIATXQEXBT-UHFFFAOYSA-N 0.000 description 1
- POWRQOUEUWZUNQ-UHFFFAOYSA-N didecyl phosphite Chemical compound CCCCCCCCCCOP([O-])OCCCCCCCCCC POWRQOUEUWZUNQ-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229920006226 ethylene-acrylic acid Polymers 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- ADFPJHOAARPYLP-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;styrene Chemical compound COC(=O)C(C)=C.C=CC1=CC=CC=C1 ADFPJHOAARPYLP-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- LQZRZCBAQVJHDZ-UHFFFAOYSA-N phenyl tridecyl phosphite Chemical compound CCCCCCCCCCCCCOP([O-])OC1=CC=CC=C1 LQZRZCBAQVJHDZ-UHFFFAOYSA-N 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229920002285 poly(styrene-co-acrylonitrile) Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- KCTAWXVAICEBSD-UHFFFAOYSA-N prop-2-enoyloxy prop-2-eneperoxoate Chemical compound C=CC(=O)OOOC(=O)C=C KCTAWXVAICEBSD-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001721 transfer moulding Methods 0.000 description 1
- FWIRRLPRKXPJHT-UHFFFAOYSA-N tris(2,3-dioctylphenyl) phosphite Chemical compound CCCCCCCCC1=CC=CC(OP(OC=2C(=C(CCCCCCCC)C=CC=2)CCCCCCCC)OC=2C(=C(CCCCCCCC)C=CC=2)CCCCCCCC)=C1CCCCCCCC FWIRRLPRKXPJHT-UHFFFAOYSA-N 0.000 description 1
- HBRCXLIZJKBWEO-UHFFFAOYSA-N tris[2,3,4-tri(nonyl)phenyl] phosphite Chemical compound CCCCCCCCCC1=C(CCCCCCCCC)C(CCCCCCCCC)=CC=C1OP(OC=1C(=C(CCCCCCCCC)C(CCCCCCCCC)=CC=1)CCCCCCCCC)OC1=CC=C(CCCCCCCCC)C(CCCCCCCCC)=C1CCCCCCCCC HBRCXLIZJKBWEO-UHFFFAOYSA-N 0.000 description 1
- 229920006337 unsaturated polyester resin Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯è¡æ¶²æ€æ»çšå®¹åšã«é¢ãã詳ããã¯ã被
æ€è
ã®å
šè¡è©Šæããé å¿åé¢ã«ãããè¡æž
ãåé¢
ããããã«çšããæåºã®ç®¡ç¶å®¹åšãæè¬ã¹ããã
ã«é¢ããã
è¿å¹Žãæ€æ»æè¡ã®ç®ããŸããé²æ©ãšçžä¿ã€ãŠã
è¡æž
çååŠæ€æ»ãè¡æž
å
ç«åŠæ€æ»ãè¡çæ€æ»çã®
è¡æ¶²æ€æ»ãåºãæ®åããç
æ°äºé²ãæ©æ蚺æã«å€§
ããè²¢ç®ããã«è³ã€ãŠãããè¡æž
æ€æ»ã¯ãè¡æ¶²æ€
æ»ã®äž»äœããªããŠãããæ€æ»ã«èŠããè¡æž
ã¯é
åžžãè¡æ¶²æ€æ»çšå®¹åšã«æ¡åããè¡æ¶²ãååºããã
åŸãé å¿åé¢ã«ãã€ãŠãæ¯éã®ç°ãªãè¡é€
ïŒãã€
ããªã³ãšè¡çãæ··åããã²ã«æ§å¡ç¶ç©ïŒããåé¢
ããŠããã
åŸæ¥ã®è¡æ¶²æ€æ»çšå®¹åšãšããŠã¯ãã¬ã©ã¹è£œã®ã
ã®ãåã³ãããªã¹ãã¬ã³ãããªã¡ãã«ã¡ã¿ã¯ãªã¬
ãŒããããªãšãã¬ã³çã®åææš¹è補ã®ãã®ã䜿çš
ãããŠãããããããã¯æŠããŠä»¥äžã®æ¬ ç¹ãæã€
ãŠããã
äžã€ã¯è¡æ¶²æ€æ»çšå®¹åšã«è¡æ¶²ã泚å
¥ããåŸãå
åºã«è³ããŸã§ã«ããªãã®æéãå¿
èŠãšããè¿
éã«
æ€æ»ãå®æœããããšãã§ããªãç¹ã§ãããç¹ã«ç·
æ¥ã«æ€æ»ãå®æœããå¿
èŠã®ããå Žåã«åé¡ãšãªã€
ãŠãããæãè¡æ¶²ååºæéãçãããšãããã¬ã©
ã¹è£œè¡æ¶²æ€æ»çšå®¹åšã§ãããè¡æ¶²ã泚å
¥ããåŸå
åºã«è³ããŸã§ã«40åãªãã60åãå¿
èŠãšããåæ
æš¹è補è¡æ¶²æ€æ»çšå®¹åšã«è³ã€ãŠã¯ãè¡æ¶²ååºãã
ãŸã§ã«ãïŒæé以äžã®æŸçœ®ãå¿
èŠãšããã
åŸæ¥ã®è¡æ¶²æ€æ»çšå®¹åšã®æããããŸã²ãšã€ã®æ¬
ç¹ã¯ãååºããå
šè¡ãé å¿åé¢çã®æ段ã«ãã€ãŠ
æ¯éã®ç°ãªãè¡æž
ãšè¡é€
ã«çžåé¢ãããŠãæ€æ»ã«
䜿çšããçŽç²ãªè¡æž
ãæ¡åããã«éããè¡æž
ã®å
é¢æ§ãæŠããŠäžè¯ã§ããããšã§ããã
å³ã¡ã²ã«ç¶ã®ãã€ããªã³ãããã¯è¡é€
ã管å£ã«
匷åºã«ä»çãæãããã®ãããè¡æž
ã®æ¡åéã極
端ã«æžå°ãããåé¡ããããåãè¡æž
äžã«ãã€ã
ãªã³ãæ®åãæãããã®ãããè¡æž
çååŠæ€æ»ã«
é害ãã²ãèµ·ãããªã©ã®åé¡ãåããŠããããã
ãŠè¡æž
åé¢æ§ãæ¯èŒçè¯å¥œãšãããã¬ã©ã¹è£œè¡æ¶²
æ€æ»çšå®¹åšã§ããã15â以äžã®äœæž©ç¶æ
ãç¹ã«å¬
æ䜿çšã«ãããŠãäžèšã®åé¡ãé »çºãããŠããã
æ¬çºæè
ãã¯ãäžèšã®æ¬ ç¹ã解æ¶ãããããè¡
液ååºãä¿é²ããäœçšãæããç©è³ªæ§é ãæ€èšã
ç¹ã«ãè¡æ¶²ååºå åãæãæå¹ã«æŽ»æ§åãããã
ã«ãè¡æ¶²æ€æ»çšå®¹åšã®å
å£é¢åœ¢æææã«ååšãã
ãã¹ãç©è³ªæ§é ãéæç 究ããçµæãè¡æ¶²ååºäœ
çšã®é¡èãªç©è³ªãšããŠãäºãªã³é
žãšã¹ãã«ãèŠåº
ãããããè¡æ¶²ååºã«èŠããæéã倧å¹
ã«ççž®ã
ãããšå
±ã«è¡æž
æåãšè¡é€
æåãè¯å¥œã«åé¢ã§ã
ãããšãèŠåºããåæŽã«ããããšïŒïŒ2â²ïŒïŒïŒ
4â²âããã©ããããã·ãã³ãŸããšãã³ãã«ãã³ãŒ
ã«èªå°äœãïœïŒpâ²âã€ãœããããªãã³ãžããšããŒ
ã«ã䜵çšããããšã«ããçžä¹çå¹æãåŸãããã
ãšãèŠåºãæ¬çºæãå®æããã«è³ã€ãã
æ¬çºæã®èŠæšãšãããšããã¯ã
ïŒ å
å£é¢åœ¢æææã«ã
åŒ
ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ããããR1ïŒR2ïŒR3ã®
ãã¡äžãããã¯äºãããšãã«åºãåã¯è©²ããšãã«
åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«åºãããã¯ãªã¯
ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ãã«ããšãã«åºã§
ãããä»ããã·ã«åºã§ãããïŒ
ã§è¡šããããäºãªã³é
žãšã¹ãã«ãååšãããŠãã
ããšãç¹åŸŽãšãããè¡æ¶²æ€æ»çšå®¹åšã
ïŒ å
å£é¢åœ¢æææã«ã
åŒ
ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ããããR1ïŒR2ïŒR3ã®
ãã¡äžãããã¯äºãããšãã«åºãåã¯è©²ããšãã«
åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«åºãããã¯ãªã¯
ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ãã«ããšãã«åºã§
ãããä»ããã·ã«åºã§ãããïŒ
ã§è¡šããããäºãªã³é
žãšã¹ãã«ïŒéééšãšãïŒïŒ
2â²ïŒïŒïŒ4â²âããã©ããããã·ãã³ãŸããšãã³0.1
ä¹è³3.0éééšãšãååšãããŠããããšãç¹åŸŽãš
ãããè¡æ¶²æ€æ»çšå®¹åšã
ïŒ å
å£é¢åœ¢æææã«ã
åŒ
ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ãããã
R1ïŒR2ïŒR3ã®ãã¡äžãããã¯äºãããšãã«åºã
åã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«
åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ã
ã«ããšãã«åºã§ãããä»ããã·ã«åºã§ãããïŒ
ã§è¡šããããäºãªã³é
žãšã¹ãã«ïŒéééšãšãïŒâ
ã¿ãŒã·ã€ãªããã«ã«ãã³ãŒã«ãïŒâã¿ãŒã·ã€ãªã
ãã«ã«ãã³ãŒã«ããã©ã¿ãŒã·ã€ãªããã«ã«ãã³ãŒ
ã«ãã«ããã³ããã³ãã«ãžãããã¬ã€ã¬ããã¯é
ž
ããéžã°ããã«ãã³ãŒã«èªå°äœ0.1ä¹è³5.0éééš
ãšãååšãããŠããããšãç¹åŸŽãšãããè¡æ¶²æ€æ»
çšå®¹åšã
ïŒ å
å£é¢åœ¢æææã«ã
åŒ
ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ãããã
R1ïŒR2ïŒR3ã®ãã¡äžãããã¯äºãããšãã«åºã
åã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«
åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ã
ã«ããšãã«åºã§ãããä»ããã·ã«åºã§ãããïŒã§
è¡šããããäºãªã³é
žãšã¹ãã«ïŒéééšãšïŒ°ïŒPâ²â
ã€ãœããããªãã³ãžããšããŒã«0.1ä¹è³5.0éééš
ãšãååšãããŠããããšãç¹åŸŽãšãããè¡æ¶²æ€æ»
çšå®¹åšã«åããã
次ã«æ¬çºæè¡æ¶²æ€æ»çšå®¹åšã«ã€ããŠæŽã«è©³çŽ°ã«
説æããã
æ¬çºæã«ãããŠãè¡æ¶²æ€æ»çšå®¹åšãå³ã¡ã¹ãã
ãã®çŽ æãšããŠã¯ãç±å¯å¡æ§æš¹èãç±ç¡¬åæ§æš¹
èãå€æ§å€©ç¶æš¹èã®ãããããçšãããããç±å¯
å¡æ§æš¹èãšããŠã¯ãäŸãã°ããªãšãã¬ã³ãããªã
ããã¬ã³ãããªâïŒâã¡ãã«ãã³ãã³âïŒãããª
ã¹ãã¬ã³ãããªã¡ãã«ã¡ã¿ã¯ãªã¬ãŒããããªå¡©å
ããã«ãããªãšãã¬ã³ãã¬ãã¿ã¬ãŒããããªãã
ã¬ã³ãã¬ãã¿ã¬ãŒããã¹ãã¬ã³âã¢ã¯ãªããããª
ã«å
±éåäœãã¹ãã¬ã³âãã¿ãžãšã³å
±éåäœãã¹
ãã¬ã³âã€ãœãã¬ã³å
±éåäœãã¹ãã¬ã³âç¡æ°Žã
ã¬ã€ã³é
žå
±éåäœãã¹ãã¬ã³âã¢ã¯ãªã«é
žå
±éå
äœãã¹ãã¬ã³âã¡ãã«ã¡ã¿ã¯ãªã¬ãŒãå
±éåäœã
ãšãã¬ã³âãããã¬ã³å
±éåäœãã¹ãã¬ã³âã¢ã¯
ãªã«é
žå
±éåäœããšãã¬ã³âã¢ã¯ãªã«é
žãšã¹ãã«
å
±éåäœãããªããã«ã¢ã«ã³ãŒã«ã¢ã»ã¿ãŒã«å
ç©ãããªããã«ã¢ã«ã³ãŒã«ããã©ãŒã«åç©çããŸ
ãç±ç¡¬åæ§æš¹èãšããŠã¯ãäŸãã°ãäžé£œåããªãš
ã¹ãã«æš¹èããšããã·æš¹èããšããã·âã¢ã¯ãªã¬
ãŒãæš¹èçãçšããããã
å€æ§å€©ç¶æš¹èãšããŠã¯ãé
¢é
žã»ã«ããŒã¹ããã
ããªã³é
žã»ã«ããŒã¹ãé
¢é
žé
ªé
žã»ã«ããŒã¹ããšã
ã«ã»ã«ããŒã¹ããšãã«ããã³çãçšããããã
æ¬çºæè¡æ¶²æ€æ»çšå®¹åšã«ãããŠã¯ãå
å£é¢ã«è¡
液ååºä¿é²äœçšãæããäºãªã³é
žãšã¹ãã«ãååš
ãããŠããã
ãããäºãªã³é
žãšã¹ãã«ãšããŠã¯ã
åŒ
ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ããããR1ïŒR2ïŒR3ã®
ãã¡äžãããã¯äºãããšãã«åºãåã¯è©²ããšãã«
åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«åºãããã¯ãªã¯
ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ãã«ããšãã«åºã§
ãããä»ããã·ã«åºã§ãããïŒ
ã§è¡šãããããã®ã䜿çšãããã
ãããŠäžåŒã«ãããŠãæ¬çºæã«ãããŠäœ¿çšã«é©
ããäºãªã³é
žãšã¹ãã«ã¯ãR1ïŒR2ïŒR3ã®çš®é¡ã«
ãã次ã®éãã«åé¡ãããã
(1) R1ïŒR2ïŒR3ãããããããšãã«åºåã¯ã¢ã«
ãã«ããšãã«åºã§ããå ŽåïŒ
äŸãã°ããªã¹ããšãã«ãã¹ãã¢ã€ããããªã¹
ïŒã¢ãããã«ããšãã«ïŒãã¹ãã¢ã€ããããªã¹
ïŒãžããã«ããšãã«ïŒãã¹ãã¢ã€ããããªã¹
ïŒããªããã«ããšãã«ïŒãã¹ãã¢ã€ããããªã¹
ïŒã¢ããªã¯ãã«ããšãã«ïŒãã¹ãã¢ã€ããããª
ã¹ïŒãžãªã¯ãã«ããšãã«ïŒãã¹ãã¢ã€ããããª
ã¹ïŒããªãªã¯ãã«ããšãã«ïŒãã¹ãã¢ã€ãçã
åããã
(2) R1ïŒR2ãããšãã«åºåã¯ã¢ã«ãã«ããšãã«
åºã§ãã€ãŠãR3ãã¢ã«ãã«åºã®å ŽåïŒ
äŸãã°ãžããšãã«ãã·ã«ãã¹ãã¢ã€ãããž
ïŒã¢ãããã«ããšãã«ïŒãã·ã«ãã¹ãã¢ã€ãã
ãžïŒãžããã«ããšãã«ïŒãã·ã«ãã¹ãã¢ã€ãã
ãžïŒããªããã«ããšãã«ïŒãã·ã«ãã¹ãã¢ã€
ãããžïŒã¢ããªã¯ãã«ããšãã«ïŒãã·ã«ãã¹ã
ã¢ã€ãããžïŒãžãªã¯ãã«ããšãã«ïŒãã·ã«ãã¹
ãã¢ã€ãããžïŒãã«ãªã¯ãã«ããšãã«ïŒãã·ã«
ãã¹ãã¢ã€ãçãåããã
(3) R1ãããšãã«åºåã¯ã¢ã«ãã«ããšãã«åºã§
ãã€ãŠãR2ïŒR3ãã¢ã«ãã«åºã®å ŽåïŒ
äŸãã°ããšãã«ããªãã·ã«ãã¹ãã¢ã€ããã
ãã«ããšãã«ãžãã·ã«ãã¹ãã¢ã€ãããžããã«
ããšãã«ãžãã·ã«ãã¹ãã¢ã€ããããªããã«ã
ãšãã«ãžãã·ã«ãã¹ãã¢ã€ããã¢ããªã¯ãã«ã
ãšãã«ãžãã·ã«ãã¹ãã¢ã€ãããžãªã¯ãã«ããš
ãã«ãžãã·ã«ãã¹ãã¢ã€ããããªãªã¯ãã«ããš
ãã«ãžãã·ã«ãã¹ãã¢ã€ãçãåããã
ãããŠäžèšã®è¡æ¶²ååºäœçšãæããäºãªã³é
žãš
ã¹ãã«ã®ãã¡ãç¹ã«å¥œé©ã«äœ¿çšããããã®ãšããŠ
ã¯ãããªã¹ïŒã¢ãããã«ããšãã«ïŒãã¹ãã¢ã€
ããããªã¹ïŒãžããã«ããšãã«ïŒãã¹ãã¢ã€ãã
ããªã¹ïŒããªããã«ããšãã«ïŒãã¹ãã¢ã€ãããž
ãã·ã«ããšãã«ãã¹ãã¢ã€ãããžããšãã«ãã·ã«
ãã¹ãã¢ã€ãçã§ããã
å
å£é¢åœ¢æææã«åèšã®äºãªã³é
žãšã¹ãã«ãå
åšããããšã¯ãäºãªã³é
žãšã¹ãã«ãå
å£è¡šé¢ã ã
ã§ãªãå£å
éšå±€ã«ãååšãããå Žåã®ããšãã
ãã
æ¬çºæè¡æ¶²æ€æ»çšå®¹åšã¯æ¬¡ã®æ¹æ³ã«ãŠã補é ã
ãããšãã§ãããæ圢ææãšããŠã®æš¹èã«äºãã
åèšã®äºãªã³é
žãšã¹ãã«ãäžæ§ã«æ··åããããã
å°åºæåããããŒæåãå§çž®æ圢ããã©ã³ã¹ãã¢
ãŒæ圢ãç空æ圢ããã€ã¹ãæ圢çé©å®ã®æ圢æ¹
æ³ã«ãã€ãŠæ圢ããããã®æ¹æ³ã«ããã°è¡æ¶²æ€æ»
çšå®¹åšã®å£å
šäœã«ãè¡šé¢ã ãã§ãªããåãæ¹åã«
ããåèšã®äºãªã³é
žãšã¹ãã«ãåæ£ãããŠããã
æ圢åŸãæŸçœ®ãããŠããéã«ãåæ£ãããŠããå
èšã®äºãªã³é
žãšã¹ãã«ã次第ã«è¡æ¶²æ€æ»çšå®¹åšã®
è¡šé¢ãžç§»è¡ããããšã«ãã€ãŠãè¡æ¶²ååºä¿é²ã«æ
å¹ãªè¡šé¢ã圢æããããåèšã®äºãªã³é
žãšã¹ãã«
ã®è¡æ¶²æ€æ»çšå®¹åšã®å
å£é¢ãžã®ç§»è¡ãããæå¹ã«
èµ·ãããæ段ãšããŠããªãŒãã¢ãŠãä¿é²ç©è³ªãæ
圢ææãšããŠã®æš¹èäžã«ãäºãåèšã®äºãªã³é
žãš
ã¹ãã«ãšå
±ã«æ··åããŠããã®ã奜é©ã§ããã
ããªãŒãã¢ãŠãä¿é²ç©è³ªãšããŠã¯ãé«çŽèèªæ
ã¢ã«ã³ãŒã«ãé«çŽèèªæã«ã«ãã³é
žããã€ããã«
ãŒãã³ã¯ãã¯ã¹ãçã®äœ¿çšãæå¹ã§ããã
åèšã®äºãªã³é
žãšã¹ãã«ã¯å®¹åšã®å
å£è¡šé¢äžã«
å
ããªéãååšããå Žåã«ãããŠãè¡æ¶²ååºä¿é²
äœçšãèªããããããå®çšäžå¥œé©ã«ã¯ãè¡šé¢ç©åœ
ãã®ååšéããïŒÃ10-6ïœïœïŒcm2以äžã§ããããš
ãæãŸãããåãäœãå€éã«ååšããå Žåã«ã¯ã
è¡æž
æ€æ»ã劚害ããããšããããããïŒÃ10-3ïœ
ïœïŒcm2以äžãšããäºãæãŸããã
äžèšã®å Žåã«ãããŠåèšã®äºãªã³é
žãšã¹ãã«ã
åç¬ã§ååšãããå Žåã«ãé¡èãªè¡æ¶²ååºä¿é²å¹
æãèªããããã
ããããªããåèšã®äºãªã³é
žãšã¹ãã«ãšïŒïŒ
2â²ïŒïŒïŒ4â²âããã©ããããã·ãã³ãŸããšãã³ã
ã«ãã³ãŒã«èªå°äœåã¯ïœïŒpâ²âã€ãœããããªãã³
ãžããšããŒã«ã䜵çšããããšã«ããè¡æ¶²ååºä¿é²
å¹æãäžå±€ãããããã®ãšããããšãã§ãããå
èšã®äºãªã³é
žãšã¹ãã«ãšäœµçšãããããšã«ããçž
ä¹çã«è¡æ¶²ååºä¿é²å¹æãçºæ®ããç©è³ªã®äžã€
ã¯ãïŒïŒ2â²ïŒïŒïŒ4â²âããã©ããããã·ãã³ãŸã
ãšãã³ã§ããã
ïŒïŒ2â²ïŒïŒïŒ4â²âããã©ããããã·ãã³ãŸããš
ãã³ã¯æ¬¡ã®ååŠæ§é åŒãæããã
ïŒïŒ2â²ïŒïŒïŒ4â²âããã©ããããã·ãã³ãŸããš
ãã³ã¯èç¹ã195âã溶åªã«å¯Ÿãã溶解æ§ã¯30â
ã§æ°Žã«å¯Ÿã0.1ééïŒ
ãã¡ã¿ããŒã«ã«å¯Ÿã50éé
ïŒ
ããšã¿ããŒã«ã«å¯Ÿã40ééïŒ
ãæ°Žâãšã¿ããŒã«
ã®ïŒïŒïŒæº¶æ¶²ã«å¯Ÿã10ééïŒ
ã§ããã
åãæ倧åžåæ³¢é·äœçœ®ã¯345ïœÎŒã§ãããã«ã©
ãŒããªãŠãŒïŒã¬ãŒãããŒïŒã¯ïŒééïŒ
ã®ã¡ã¿ããŒ
ã«æº¶æ¶²ã«ãããŠNo.ïŒã§ããã
ïŒïŒ2â²ïŒïŒïŒ4â²âããã©ããããã·ãã³ãŸããš
ãã³ã®äœ¿çšééæ¯çã¯äºãªã³é
žãšã¹ãã«ïŒã«å¯Ÿ
ãã0.1ä¹è³3.0ã奜é©ã§ããã
åèšäºãªã³é
žãšã¹ãã«ãšäœµçšãããããšã«ãã
çžä¹çã«è¡æ¶²ååºä¿é²äœçšãçºæ®ããä»ã®ç©è³ªã¯
ã«ãã³ãŒã«èªå°äœã§ããã
ã«ãã³ãŒã«èªå°äœãšããŠã¯æ¬¡ã®åŒã§è¡šãããã
ãã®ã䜿çšãããã
äžåŒã®å Žåã«ãããŠã«ãã³ãŒã«èªå°äœã¯ãR1ïŒ
R2ïŒR3ã®çš®é¡ã«ããïŒâã¢ã«ãã«ã«ãã³ãŒã«ã
ïŒâã¢ã«ãã«ã«ãã³ãŒã«ããã©ã¢ã«ãã«ã«ãã³ãŒ
ã«ãã«ããã³ããã«ãžãããã¬ã€ã¬ããã¯é
žãšã©
ãžã³é
žçã«åããããããããŠãããã®äžã§ãç¹
ã«çžä¹å¹æãé¡èã«ç€ºããã®ã¯ãïŒâã¿ãŒã·ã€ãª
ããã«ã«ãã³ãŒã«ãïŒâã¿ãŒã·ã€ãªããã«ã«ãã³
ãŒã«ããã©ã¿ãŒã·ã€ãªããã«ã«ãã³ãŒã«ãã«ãã
ã³ããã«ãžãããã¬ã€ã¬ããã¯é
žã§ããã
åèšã«ãã³ãŒã«èªå°äœã®äœ¿çšééæ¯éã¯åèšäº
ãªã³é
žãšã¹ãã«ïŒã«å¯Ÿã0.1ä¹è³5.0ã奜é©ã§ã
ãã
åèšäºãªã³é
žãšã¹ãã«ãšäœµçšãããããšã«ãã
çžä¹çã«è¡æ¶²ååºä¿é²å¹æãçºæ®ããä»ã®ç©è³ªã¯
ïœïŒpâ²âã€ãœããããªãã³ãžããšããŒã«ã§ããã
ããã¯ãã¹ããšããŒã«ïŒ¡ãšããŠåååãããŠãã
ç©è³ªã§ããããšããã·æš¹èã®è£œé åæãšããŠäœ¿çš
ãããŠããããè¡æ¶²ååºä¿é²å¹æãæããããšã¯
ç¥ãããŠããªãã€ããïœïŒpâ²âã€ãœããããªãã³
ãžããšããŒã«ã®äœ¿çšééæ¯çã¯ãåèšäºãªã³é
žãš
ã¹ãã«ïŒã«å¯Ÿã0.1ä¹è³5.0ã奜é©ã§ããã
æ¬çºæè¡æ¶²æ€æ»çšå®¹åšã«ããã°è¡æ¶²ååºå åã
è¿
éã«æŽ»æ§åããããããè¡æ¶²ååºã«èŠããæé
ãèããççž®ããããšå
±ã«è¡æž
ãšè¡é€
ãšã®åé¢ã
容æã«è¡ãªãããåé¢æ¡åãããè¡æž
äžã«æ®åã
ã€ããªã³ãè¡é€
æåãæ··å
¥ããåé¡ã解æ¶ããã
æŽã«ã¯è¡é€
æåã®åçž®ãååã«é²è¡ããçµæãè¡
æž
ã®åéãèãã倧ãããªãå¹æãåŸãããã
åŸã€ãŠãæ¬çºæè¡æ¶²æ€æ»çšå®¹åšã¯è¡æ¶²æ€æ»çšæ¡
è¡ç®¡ãè¡æ¶²åé¢ç®çãæããæ¡è¡çšã·ãªã³ãžãè¡
æž
åé¢å®¹åšçã®çšéã«å¥œé©ã«äœ¿çšããããšãã§ã
ãã
å®æœäŸ ïŒ
ããªãããã¬ã³100éééšåœãããªã¹ïŒã¢ãã
ãã«ããšãã«ïŒãã¹ãã¢ã€ã1.5éééšãæ·»å ã
ãæ圢ææãå°åºæ圢ããå€åŸ17ïœïŒïœãå
åŸ15
ïœïŒïœãé«ã110ïœïŒïœã®è¡æ¶²æ€æ»çšå®¹åšãåŸãã
ãã®è¡æ¶²æ€æ»çšå®¹åšã«äººæ°é®®è¡ïŒc.c.ã泚å
¥ãã
åŸ20âã§æŸçœ®ããŠãå
šè¡ãå®å
šã«æµåããªããªã
ãŸã§ã«èŠããæéãè¡æ¶²ååºæéãšããŠæž¬å®ãã
è¡æ¶²ååºæ§ãè©äŸ¡ããã
è¡æ¶²ååºåŸãçŽã¡ã«3000å転ïŒæ¯åã®å転é床
ã§ãïŒåéé å¿åé¢ãè¡ãªããè¡æž
åé¢ç¶æ
ã芳
å¯ãããšå
±ã«ãäžæŸã¿è¡æž
ãããããã«ãŠæ¡å
ãããã®éãè¡æž
åéãšããã
è¡šïŒã®å®æœäŸïŒã®æ¬ã®çµæããæãããªãã
ã«ãæ¬çºæã®è¡æ¶²æ€æ»çšå®¹åšã¯ãè¡æ¶²ååºã極ã
ãŠéããã§ãããè¡æž
åé¢ç¶æ
ãè¯å¥œã§ãã€ãã
å®æœäŸ ïŒãïŒ
å®æœäŸïŒã«ãããŠããªã¹ïŒã¢ãããã«ããšã
ã«ïŒãã¹ãã¢ã€ã1.5éééšã®ä»£ãã«ããªã¹ïŒãž
ããã«ããšãã«ïŒãã¹ãã¢ã€ã2.0éééšã䜿çš
ããçµæã®æ圢ææïŒå®æœäŸïŒïŒãããªã¹ïŒã¢ã
ããã«ããšãã«ïŒãã¹ãã¢ã€ã1.5éééšã®ä»£ã
ã«ãžããšãã«ãã·ã«ãã¹ãã¢ã€ã2.0éééšã䜿
çšããçµæã®æ圢ææïŒå®æœäŸïŒïŒãã倫ã
å®æœ
äŸïŒãšåæ§ã«ããŠè¡æ¶²æ€æ»çšå®¹åšãåŸãã
次ãã§ãã®è¡æ¶²æ€æ»çšå®¹åšã䜿çšããå®æœäŸïŒ
ãšåæ§ã«ããŠè¡æ¶²ååºæ§ãè¡æž
åé¢ç¶æ
ãè¡æž
å
éãè©äŸ¡ããããã®çµæãè¡šïŒã®å®æœäŸïŒïŒïŒã®
æ¬ã«ç€ºãã
å®æœäŸ ïŒãïŒ
ã¹ãã¬ã³âãã¿ãžãšã³å
±éåäœ100éééšåœãã
ããªã¹ïŒãžããã«ããšãã«ïŒãã¹ãã¢ã€ã1.5é
ééšãïŒïŒ2â²ïŒïŒïŒ4â²âããã©ãããããžãã³ãŸ
ããšãã³0.7éééšã䜵çšããçµæã®æ圢ææ
ïŒå®æœäŸïŒïŒãã¹ãã¬ã³âãã¿ãžãšã³å
±éåäœ100
éééšåœããããªã¹ïŒãžããã«ããšãã«ïŒãã¹ã
ã¢ã€ã1.5éééšãïŒâã¿ãŒã·ã€ãªãŒããã«ã«ã
ã³ãŒã«0.7éééšã䜵çšããçµæã®æ圢ææïŒå®
æœäŸïŒïŒãã¹ãã¬ã³âãã¿ãžãšã³å
±éåäœ100éé
éšåœããããªã¹ïŒãžããã«ããšãã«ïŒãã¹ãã¢ã€
ã1.5éééšãïœïŒpâ²âã€ãœããããªãã³ãžããš
ããŒã«0.7éééšã䜵çšããçµæã®æ圢ææïŒå®
æœäŸïŒïŒãçšããŠå€«ã
å®æœäŸïŒãšåæ§ã«è¡æ¶²æ€æ»
çšå®¹åšãåŸãã
次ãã§ãã®è¡æ¶²æ€æ»çšå®¹åšã䜿çšããå®æœäŸïŒ
ãšåæ§ã«ããŠè¡æ¶²ååºæ§ãè¡æž
åé¢ç¶æ
ãè¡æž
å
éãè©äŸ¡ããããã®çµæã¯è¡šïŒã®å®æœäŸïŒãïŒã®
æ¬ã«ç€ºãããè¡æ¶²ååºä¿é²ã«ãããé¡èãªçžä¹å¹
æãèªãããããšå
±ã«è¡æž
åé¢ç¶æ
ã極ããŠè¯å¥œ
ã§ãã€ãã
æ¯èŒäŸ ïŒãïŒ
å®æœäŸïŒã«ããããšåäžå¯žæ³ã®åžè²©ã®ããªã¹ã
ã¬ã³è£œè¡æ¶²æ€æ»çšå®¹åšïŒæ¯èŒäŸïŒïŒãããªããã
ã¬ã³è£œè¡æ¶²æ€æ»çšå®¹åšïŒæ¯èŒäŸïŒïŒåã³ããªã¡ã
ã«ã¡ã¿ã¯ãªã¬ãŒã補è¡æ¶²æ€æ»çšå®¹åšïŒæ¯èŒäŸïŒïŒ
ãçšæããå®æœäŸïŒã«ããããšåæ¡ä»¶äžã«è¡æ¶²å
åºæ§ãè¡æž
åé¢ç¶æ
ãè¡æž
åéãè©äŸ¡ããããè¡
液ååºæéãèããé·æéãšãªããåè¡æž
åé¢ç¶
æ
ãäžè¯ã§ãã€ãã
ãè¡šãDETAILED DESCRIPTION OF THE INVENTION The present invention relates to a blood test container, and more particularly to a so-called spitz, a bottomed tubular container used for separating serum from a whole blood sample of a subject by centrifugation. In recent years, coupled with the remarkable progress in inspection technology,
Blood tests such as serum biochemical tests, serum immunological tests, and hematology tests have become widely used, and have come to greatly contribute to disease prevention and early diagnosis. Serum tests are the main body of blood tests, and the serum required for tests is usually obtained by coagulating blood collected in a blood test container and then centrifuging it to form blood clots with different specific gravities (fibrin and blood cells). separated from the mixed gel-like mass). Conventional blood test containers are made of glass and synthetic resins such as polystyrene, polymethyl methacrylate, and polyethylene, but these generally have the following drawbacks. One is that it takes a considerable amount of time for blood to coagulate after it is injected into a blood test container, making it impossible to carry out tests quickly, especially when tests need to be carried out urgently. has become a problem. Even glass blood test containers, which are said to have the shortest blood clotting time, require 40 to 60 minutes for blood to coagulate after being injected, and synthetic resin blood test containers... It takes 4 hours or more for the blood to coagulate. Another drawback of conventional blood test containers is that they require a method such as centrifugation to phase-separate coagulated whole blood into serum and blood clots with different specific gravities to collect pure serum for use in tests. , serum separability is generally poor. In other words, gel-like fibrin or blood clots tend to adhere firmly to the tube wall, which causes the problem of drastically reducing the amount of serum collected.Furthermore, fibrin tends to remain in the serum, which makes it difficult to perform serum biochemical tests. There were problems such as causing problems. Even glass blood test containers, which are said to have relatively good serum separation, frequently suffer from the above-mentioned problems when used at low temperatures of 15° C. or lower, especially during winter. In order to eliminate the above-mentioned drawbacks, the present inventors investigated the structure of substances that have the effect of promoting blood coagulation, and in particular, in order to most effectively activate blood coagulation factors, the inventors of the present invention have investigated the formation of the inner wall surface of blood test containers. As a result of intensive research into the substance structure that should be present in the material, we discovered phosphite as a substance with a remarkable blood coagulation effect, and found that this significantly shortened the time required for blood coagulation and improved the concentration of serum and clot components. We found that it was possible to separate this from 2, 2', 4,
The present inventors have discovered that a synergistic effect can be obtained by using 4'-tetrahydroxybenzophenone, a catechol derivative, and p,p'-isopropylidene diphenol in combination, and have completed the present invention. The gist of the present invention is as follows: 1. Inner wall surface forming material, formula: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group.) A container for blood testing, characterized in that a phosphite ester represented by the following formula is present: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group.) 1 part by weight of a phosphite ester represented by
2',4,4'-tetrahydroxybenzophenone 0.1
3. A container for blood testing, characterized in that the inner wall surface forming material is present with the formula: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) 1 part by weight of a phosphite ester represented by
A blood test characterized by the presence of 0.1 to 5.0 parts by weight of a catechol derivative selected from tertiary butylcatechol, 4-tertiarybutylcatechol, paratertiarybutylcatechol, catechin, and nordihydrogayaretic acid. 4. For the inner wall surface forming material, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) and 1 part by weight of phosphite ester represented by P, P'-
The present invention provides a blood test container characterized by containing 0.1 to 5.0 parts by weight of isopropylidene diphenol. Next, the blood test container of the present invention will be explained in more detail. In the present invention, any of thermoplastic resins, thermosetting resins, and modified natural resins can be used as the material for the blood test container, that is, the spittoon. Examples of thermoplastic resins include polyethylene, polypropylene, poly-4-methylpentene-1, polystyrene, polymethyl methacrylate, polyvinyl chloride, polyethylene terephthalate, polybutylene terephthalate, styrene-acrylonitrile copolymer, and styrene-butadiene copolymer. , styrene-isoprene copolymer, styrene-maleic anhydride copolymer, styrene-acrylic acid copolymer, styrene-methyl methacrylate copolymer,
Ethylene-propylene copolymer, styrene-acrylic acid copolymer, ethylene-acrylic acid ester copolymer, polyvinyl alcohol acetal, polyvinyl alcohol butyral, etc., and thermosetting resins include, for example, unsaturated polyester resin, Epoxy resin, epoxy-acrylate resin, etc. are used. As the modified natural resin, cellulose acetate, cellulose propionate, cellulose acetate butyrate, ethyl cellulose, ethyl chitin, etc. are used. In the blood test container of the present invention, a phosphite having a blood coagulation promoting effect is present on the inner wall surface. As such a phosphite ester, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group.) is used. In the above formula, phosphorous esters suitable for use in the present invention are classified as follows depending on the types of R 1 , R 2 , and R 3 . (1) When R 1 , R 2 , and R 3 are all phenyl or alkylphenyl groups: For example, trisphenyl phosphite, tris (monononylphenyl) phosphite, tris (dinonylphenyl) phosphite, tris (torino) These include nilphenyl) phosphite, tris(monoctylphenyl) phosphite, tris(dioctyl phenyl) phosphite, tris(trioctylphenyl) phosphite, and the like. (2) When R 1 and R 2 are phenyl or alkylphenyl groups, and R 3 is an alkyl group: For example, diphenyldecyl phosphite, di(monononylphenyl)decyl phosphite,
di(dinonylphenyl)decyl phosphite,
Examples include di(trinonylphenyl)decyl phosphite, di(monooctyl phenyl) decyl phosphite, di(dioctyl phenyl) decyl phosphite, and di(toluoctylphenyl) decyl phosphite. (3) When R 1 is a phenyl group or an alkylphenyl group and R 2 and R 3 are alkyl groups: For example, phenyltridecyl phosphite, nonylphenyl didecyl phosphite, dinonylphenyl didecyl Examples include phosphite, trinonylphenyl didecyl phosphite, monooctylphenyl didecyl phosphite, dioctyl phenyl didecyl phosphite, trioctyl phenyl didecyl phosphite, and the like. Among the above-mentioned phosphorous esters having a blood coagulation effect, those which are particularly preferably used include tris(mononylphenyl) phosphite, tris(dinonylphenyl) phosphite,
These include tris(trinonylphenyl) phosphite, didecyl phenyl phosphite, diphenyl decyl phosphite, and the like. Presence of the above-mentioned phosphite in the inner wall forming material refers to the case where the phosphite is present not only on the inner wall surface but also in the inner layer of the wall. The blood test container of the present invention can be manufactured by the following method. In advance, resin is used as a molding material.
The above-mentioned phosphite esters are uniformly mixed and molded by an appropriate molding method such as injection molding, blow molding, compression molding, transfer molding, vacuum molding, cast molding, or the like. According to this method, the phosphorous ester is dispersed throughout the wall of the blood test container, not only on the surface but also in the thickness direction.
After molding, while the container is left standing, the dispersed phosphite gradually migrates to the surface of the blood test container, thereby forming a surface effective for promoting blood coagulation. As a means to more effectively cause the transfer of the phosphite ester to the inner wall surface of the blood test container, a bleed-out promoting substance is mixed in advance with the phosphite ester into the resin serving as the molding material. is preferable. As the bleed-out accelerator, higher aliphatic alcohols, higher aliphatic carboxylic acids, hydrocarbon waxes, and the like are effective. Although the above-mentioned phosphite has a blood coagulation promoting effect even when present in a small amount on the inner wall surface of the container, it is preferable for practical use that the amount present per surface area is 1Ã10 -6 gr. / cm2 or more is desirable. Also, if there is too much,
1Ã10 -3 g as it may interfere with serum tests.
It is desirable that it be less than r/cm 2 . In the above case, when the phosphite ester is present alone, a significant blood coagulation promoting effect is observed. However, the above phosphite ester and 2,
2',4,4'-tetrahydroxybenzophenone,
By using a catechol derivative or p,p'-isopropylidene diphenol in combination, the effect of promoting blood coagulation can be further improved. One of the substances that exhibits a synergistic blood coagulation promoting effect when used in combination with the above-mentioned phosphite is 2,2',4,4'-tetrahydroxybenzophenone. 2,2',4,4'-tetrahydroxybenzophenone has the following chemical structure. 2,2',4,4'-tetrahydroxybenzophenone has a melting point of 195â and a solubility in solvents of 30â.
0.1% by weight for water, 50% by weight for methanol, 40% by weight for ethanol, and 10% by weight for a 1:1 water-ethanol solution. Further, the maximum absorption wavelength position is 345 mΌ, and the color value (Gardner) is No. 8 in a 1% by weight methanol solution. The weight ratio of 2,2',4,4'-tetrahydroxybenzophenone to 1 part of phosphite is preferably 0.1 to 3.0. Other substances that synergistically exhibit a blood coagulation promoting effect when used in combination with the phosphite are catechol derivatives. As the catechol derivative, one represented by the following formula is used. In the case of the above formula, the catechol derivative is R 1 ,
Depending on the type of R 2 and R 3, 3-alkylcatechol,
It is divided into 4-alkylcatechol, para-alkylcatechol, catechin, nordihydrogayaretic acid, ellagic acid, etc. Among these, those which show particularly remarkable synergistic effects are 3-tert-butylcatechol, 4-tert-butylcatechol, para-tert-butylcatechol, catechin, and nordihydrogayaretic acid. The weight specific gravity of the catechol derivative used is preferably 0.1 to 5.0 based on 1 part of the phosphorous acid ester. Another substance that synergistically exhibits a blood coagulation promoting effect when used in combination with the phosphite is p,p'-isopropylidene diphenol.
This is a substance commercialized as bisphenol A, and has been used as a raw material for producing epoxy resins, but it was not known to have a blood coagulation promoting effect. The weight ratio of p,p'-isopropylidene diphenol to 1 part of the phosphite is preferably 0.1 to 5.0. According to the blood test container of the present invention, blood coagulation factors are activated rapidly, the time required for blood coagulation is significantly shortened, and serum and blood clots can be easily separated, and blood coagulation factors can be rapidly activated. The problem of contamination with residual fibrin and blood clot components has also been resolved.
Furthermore, as a result of sufficient contraction of the blood clot components, the yield of serum can be significantly increased. Therefore, the blood test container of the present invention can be suitably used for blood test blood collection tubes, blood collection syringes that also serve the purpose of blood separation, serum separation containers, and the like. Example 1 A molding material containing 1.5 parts by weight of tris(monononylphenyl) phosphite per 100 parts by weight of polypropylene was injection molded, and the outer diameter was 17 m/m and the inner diameter was 15 m.
A blood test container with a height of 110 m/m and a height of 110 m/m was obtained. After injecting 5 c.c. of fresh human blood into this blood test container, it was left at 20°C, and the time required for the whole blood to stop flowing completely was measured as the blood coagulation time.
Blood coagulability was evaluated. Immediately after blood coagulation, centrifugation was performed at a rotational speed of 3000 rpm for 5 minutes, and the state of serum separation was observed, and the supernatant serum was collected with a pipette, and the amount was taken as the serum yield. As is clear from the results in the Example 1 column of Table 1, the blood test container of the present invention coagulated blood extremely quickly and had good serum separation. Examples 2 to 3 A molding material having a composition in which 2.0 parts by weight of tris(dinonylphenyl) phosphite was used instead of 1.5 parts by weight of tris(monononylphenyl) phosphite in Example 1 (Example 2), tris(monononylphenyl) ) Blood test containers were obtained in the same manner as in Example 1 from the molding material (Example 3) using 2.0 parts by weight of diphenyldecyl phosphite instead of 1.5 parts by weight of phosphite. Next, using this blood test container, Example 1
Blood coagulability, serum separation status, and serum yield were evaluated in the same manner as above. The results are shown in the columns of Examples 2 and 3 in Table 1. Examples 4 to 6 Per 100 parts by weight of styrene-butadiene copolymer,
Molding material containing 1.5 parts by weight of tris(dinonylphenyl) phosphite and 0.7 parts by weight of 2,2',4,4'-tetrahydrokidibenzophenone (Example 4), styrene-butadiene copolymer 100
Molding material containing 1.5 parts by weight of tris(dinonylphenyl) phosphite and 0.7 parts by weight of 4-tert-butylcatechol (Example 5), per 100 parts by weight of styrene-butadiene copolymer, tris(dinonylphenyl) Blood test containers were obtained in the same manner as in Example 1 using a molding material (Example 6) having a composition containing 1.5 parts by weight of phosphite and 0.7 parts by weight of p,p'-isopropylidene diphenol. Next, using this blood test container, Example 1
Blood coagulability, serum separation status, and serum yield were evaluated in the same manner as above. The results are shown in the columns of Examples 4 to 6 in Table 1, and a remarkable synergistic effect in promoting blood coagulation was observed, as well as an extremely good serum separation condition. Comparative Examples 1 to 3 Commercially available polystyrene blood test containers with the same dimensions as in Example 1 (Comparative Example 1), polypropylene blood test containers (Comparative Example 2), and polymethyl methacrylate blood test containers (Comparative Example 3)
was prepared and evaluated for blood coagulation, serum separation state, and serum yield under the same conditions as in Example 1, but the blood coagulation time was extremely long and the serum separation state was also poor. ãtableã
Claims (1)
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ãããã R1ïŒR2ïŒR3ã®ãã¡äžãããã¯äºãããšãã«åºã
åã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«
åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ã
ã«ããšãã«åºã§ãããä»ããã·ã«åºã§ãããïŒ ã§è¡šããããäºãªã³é žãšã¹ãã«ãååšãããŠãã
ããšãç¹åŸŽãšãããè¡æ¶²æ€æ»çšå®¹åšã ïŒ å å£é¢åœ¢æææã«ã åŒ ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ãããã R1ïŒR2ïŒR3ã®ãã¡äžãããã¯äºãããšãã«åºã
åã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«
åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ã
ã«ããšãã«åºã§ãããä»ããã·ã«åºã§ãããïŒ ã§è¡šããããäºãªã³é žãšã¹ãã«ïŒéééšãšãïŒïŒ
2â²ïŒïŒïŒ4â²âããã©ããããã·ãã³ãŸããšãã³
ïŒ0.1ä¹è³3.0éééšãšãååšãããŠããããšãç¹
城ãšãããè¡æ¶²æ€æ»çšå®¹åšã ïŒ å å£é¢åœ¢æææã« åŒ ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ãããã R1ïŒR2ïŒR3ã®ãã¡äžãããã¯äºãããšãã«åºã
åã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«
åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ã
ã«ããšãã«åºã§ãããä»ããã·ã«åºã§ãããïŒ ã§è¡šããããäºãªã³é žãšã¹ãã«ïŒéééšãšãïŒâ
ã¿ãŒã·ã€ãªããã«ã«ãã³ãŒã«ãïŒâã¿ãŒã·ã€ãªã
ãã«ã«ãã³ãŒã«ããã©ã¿ãŒã·ã€ãªããã«ã«ãã³ãŒ
ã«ãã«ããã³ããã³ãã«ãžãããã¬ã€ã¬ããã¯é ž
ããéžã°ããã«ãã³ãŒã«èªå°äœ0.1ä¹è³5.0éééš
ãšãååšãããŠããããšãç¹åŸŽãšãããè¡æ¶²æ€æ»
çšå®¹åšã ïŒ å å£é¢åœ¢æææã«ã åŒ ïŒäžåŒã«ãããŠãR1ïŒR2ïŒR3ã¯ããããããš
ãã«åºãåã¯è©²ããšãã«åºã®æ°ŽçŽ ååã®ïŒãïŒå
ãããã«åºãããã¯ãªã¯ãã«åºã«ãã€ãŠçœ®æãã
ãã¢ã«ãã«ããšãã«åºã§ããããR1ïŒR2ïŒR3ã®
ãã¡äžãããã¯äºãããšãã«åºãåã¯è©²ããšãã«
åºã®æ°ŽçŽ ååã®ïŒãïŒåãããã«åºãããã¯ãªã¯
ãã«åºã«ãã€ãŠçœ®æãããã¢ã«ãã«ããšãã«åºã§
ãããä»ããã·ã«åºã§ãããïŒ ã§è¡šããããäºãªã³é žãšã¹ãã«ïŒéééšãšïœïŒ
pâ²âã€ãœããããªãã³ãžããšããŒã«0.1ä¹è³5.0é
ééšãšãååšãããŠããããšãç¹åŸŽãšãããè¡æ¶²
æ€æ»çšå®¹åšã[Claims] 1. The inner wall surface forming material has the following formula: (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) A blood test container characterized by containing a phosphite ester represented by: 2 For the inner wall surface forming material, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) 1 part by weight of a phosphite ester represented by
A container for blood testing, characterized in that 2',4,4'-tetrahydroxybenzophenone (0.1 to 3.0 parts by weight) is present. 3 Inner wall surface forming material: Formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , R 3 is a phenyl group,
Alternatively, the phenyl group is an alkylphenyl group in which 1 to 3 hydrogen atoms are substituted with a nonyl group or an octyl group, and the others are decyl groups. ) 1 part by weight of a phosphite ester represented by
A blood test characterized by the presence of 0.1 to 5.0 parts by weight of a catechol derivative selected from tertiary butylcatechol, 4-tertiarybutylcatechol, paratertiarybutylcatechol, catechin, and nordihydrogayaretic acid. container. 4 For the inner wall surface forming material, the formula (In the above formula, R 1 , R 2 , and R 3 are all phenyl groups, or alkylphenyl groups in which 1 to 3 hydrogen atoms of the phenyl group are substituted with nonyl groups or octyl groups. , one or two of R 1 , R 2 , and R 3 is a phenyl group, or an alkyl phenyl group in which 1 to 3 hydrogen atoms of the phenyl group are substituted with a nonyl group or an octyl group, and others is a decyl group) and 1 part by weight of a phosphite represented by p,
A container for blood testing, characterized in that 0.1 to 5.0 parts by weight of p'-isopropylidene diphenol is present.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8734181A JPS57201852A (en) | 1981-06-05 | 1981-06-05 | Container for blood inspection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8734181A JPS57201852A (en) | 1981-06-05 | 1981-06-05 | Container for blood inspection |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57201852A JPS57201852A (en) | 1982-12-10 |
JPS6367859B2 true JPS6367859B2 (en) | 1988-12-27 |
Family
ID=13912162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8734181A Granted JPS57201852A (en) | 1981-06-05 | 1981-06-05 | Container for blood inspection |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57201852A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06242106A (en) * | 1993-02-01 | 1994-09-02 | Becton Dickinson & Co | Blood-gathering apparatus |
-
1981
- 1981-06-05 JP JP8734181A patent/JPS57201852A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS57201852A (en) | 1982-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Claude | Fractionation of mammalian liver cells by differential centrifugation: II. Experimental procedures and results | |
Perper et al. | Purification of lymphocytes and platelets by gradient centrifugation | |
US10064404B2 (en) | Stabilization of thrombocytes at ambient temperatures | |
EP2334307B1 (en) | Multilayered blood product | |
FR2704418A1 (en) | Tube containing an activator of blood coagulation and its method of preparation | |
Papahadjopoulos et al. | Purification and properties of bovine factor V: A change of molecular size during blood coagulation | |
JP2550232B2 (en) | Blood separating agent | |
JPS6367856B2 (en) | ||
DE69221849T2 (en) | Serum and plasma separating mixtures and blood test containers | |
JPS6367857B2 (en) | ||
JPS6367859B2 (en) | ||
JPH052015A (en) | Blood separating agent | |
US4529711A (en) | Fluid blood coagulation promoter | |
JPS6367660B2 (en) | ||
JP2965359B2 (en) | Blood test container | |
JPS606866A (en) | Vessel for inspecting blood | |
US4088753A (en) | Method of obtaining a splenic composition which inhibits platelet function and said composition | |
JPS6367858B2 (en) | ||
JPS6319824B2 (en) | ||
JPH0295257A (en) | Composition for separation of blood component and vessel for blood inspection | |
JPS6367658B2 (en) | ||
Grauer et al. | Immunosuppressive serum factors in viral hepatitis. III. Prognostic relevance of rosette inhibitory factor and serum inhibition factor in acute and chronic hepatitis | |
JPH0126504B2 (en) | ||
JPS596655B2 (en) | Blood collection tube for serum separation | |
JPH0126025B2 (en) |